Caluire Et Cuire

Researchers are studying patients with metastatic colorectal cancer (mCRC) who have a specific BRAFV600E mutation. This rare subtype of mCRC has poor prognosis and resistance to current treatments, especially in tumors with microsatellite stability or proficient mismatch repair. The study aims to collect detailed clinical data and biological samples to better understand treatment outcomes, resistance, and survival in real-world settings. Participants will provide blood samples and tumor tissue samples to support various research goals. The study will evaluate circulating tumor DNA during different lines of metastatic treatment to predict treatment response and resistance. It will also analyze the immune environment of BRAFV600E mCRC tumors and study specific subgroups with mismatch repair deficiencies. Clinical management data will be collected to inform future therapeutic approaches. During the study, patients will be monitored regularly with blood sample collections of 30 mL at each time point. Researchers will gather information about treatments, survival, and biological markers over time. The main outcome measured is overall survival from diagnosis up to five years. Patients must be able to comply with study procedures and provide informed consent. The study aims to improve knowledge of this aggressive cancer subtype and support development of new treatments.

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints and skin in people with psoriasis. This study aims to evaluate how well zasocitinib (TAK-279) works in adults with active PsA, considering their prior treatment experiences with specific medications. The study is a Phase 3 trial that compares zasocitinib to a placebo in participants who have or have not been treated with biologic medicines. Participants will receive either zasocitinib tablets or a matching placebo. The study is randomized, double-blind, and placebo-controlled. Treatment will continue with monitoring over a period of up to 60 weeks to assess the effects and safety of zasocitinib. During the study, participants will undergo assessments of joint and skin symptoms, including tender and swollen joint counts and evaluations of psoriatic skin lesions. Researchers will measure how many participants achieve a significant improvement in their arthritis symptoms by Week 16. Safety and response will be monitored throughout the study period, with detailed follow-up visits and evaluations to understand the treatment's impact over time.

Psoriatic arthritis (PsA) is a type of arthritis that causes joint swelling and stiffness and is often seen in people with the skin condition psoriasis. It results from an overactive immune system attacking healthy tissue. This research aims to describe the long-term use and effectiveness of risankizumab (RZB) compared to other advanced treatments for managing PsA in everyday clinical care. The study is not conducted in the United States but will take place in about 15 countries and include between 900 and 1200 adult participants. Participants will be assigned in a 2 to 1 ratio to receive either risankizumab or other advanced therapeutic agents. The treatments will be given following usual medical guidelines, including approved dosing and indications, as determined by local regulations and professional standards. All study visits will occur during routine clinical care with no extra burden on participants. Participants will be followed and monitored for 24 months to observe treatment persistence. During the study, participants will continue their regular clinical visits without additional procedures or tests required by the study. Researchers will measure how many participants continue their prescribed treatment over the 24-month period. The study focuses on real-world treatment patterns and outcomes in patients with active PsA who have previously shown an inadequate response or intolerance to certain medications. Safety monitoring will align with routine clinical practice throughout the study duration.

Rheumatoid arthritis (RA) is a common inflammatory joint disease. Researchers are studying how to safely reduce the dose of the drug adalimumab in patients who have reached remission. The goal is to find the best drug concentration before starting dose reduction to lower the risk of flare-ups. This is a Phase 4 study aiming to guide doctors on managing adalimumab tapering. The study involves two main approaches: initially, all participants receive the standard adalimumab dose. Then, patients are randomly assigned to begin a tapering strategy where adalimumab injections are gradually spaced out based on disease activity scores assessed every 3 months. The tapering is personalized and monitored closely during the study. Participants will be followed for 15 months to observe flare-ups and assess how well the tapering strategy works. Researchers will monitor disease activity regularly and adjust treatment accordingly. The study includes multiple visits for clinical assessments, and safety is closely observed throughout the trial period.

Multicenter phase II trial evaluating different strategies of pre-specified fluoropyrimidine-dose adjustment according to \[U\] in DPD-deficient patients with gastrointestinal cancer.

Researchers are evaluating the effectiveness and safety of sonelokimab compared with placebo in adults with active psoriatic arthritis who have not responded well or could not tolerate anti-tumor necrosis factor alpha (TNFb1) therapy. This Phase 3, randomized, double-blind study also includes risankizumab as an active reference treatment to better understand the benefits and risks of sonelokimab for this condition. Participants will be randomly assigned to one of four groups receiving either sonelokimab at doses of 60 mg or 120 mg, placebo, or risankizumab. The treatments are given by injection under the skin. The study is conducted across multiple centers and compares the response rates after 16 weeks of treatment to evaluate improvement in psoriatic arthritis symptoms. During the trial, participants will undergo joint assessments, blood tests for specific antibodies, and evaluations of skin psoriasis. Researchers will monitor how many participants achieve at least a 50% improvement in arthritis criteria compared to placebo. Safety and side effects will be closely observed throughout the study. The total time involved includes screening, treatment, and follow-up visits to ensure thorough evaluation of both effectiveness and safety.

Researchers are investigating treatments for locally advanced anal squamous cell carcinoma, a rare but increasing cancer often linked to human papillomavirus (HPV). The study compares standard chemoradiotherapy, which combines radiation and chemotherapy with 5FU and mitomycin-C, to a new approach adding induction chemotherapy (modified DCF protocol) before the standard chemoradiotherapy. This randomized phase 3 trial aims to improve disease-related event-free survival and other outcomes such as overall survival, colostomy-free survival, treatment tolerability, response rate, and quality of life in patients with T3-T4 or N1 stage anal cancer without metastasis. Participants in the experimental group receive four cycles of induction chemotherapy (docetaxel, cisplatin, and 5-FU given every two weeks), followed by standard chemoradiotherapy consisting of 33 sessions of radiation over 6.5 weeks combined with mitomycin during weeks 1 and 5 and capecitabine taken on radiation days. The control group receives only the standard chemoradiotherapy. Radiation is delivered using intensity-modulated external irradiation (IMRT-SIB) targeting the pelvis and tumor area with specified doses. During the study, patients undergo follow-up visits starting 8 weeks after treatment, then every 4 months for two years, and every 6 months for a final year. Follow-up includes clinical exams and imaging tests such as CT and MRI. The study measures disease-related event-free survival at 2 years after treatment completion as the primary outcome. Participants must be adults aged 18 or older with measurable tumors on MRI and able to receive chemotherapy and radiotherapy, with additional health criteria assessed before enrollment.

This research evaluates two methods for managing blood flow and pressure during off-pump coronary artery bypass graft (CABG) surgery in adults with coronary artery disease. The study compares the use of postural mobilization, specifically passive leg raising, with or without noradrenaline, against the use of noradrenaline alone. The goal is to determine how often noradrenaline is needed when using postural mobilization and to compare outcomes such as revascularization rates and postoperative complications between the two approaches. Participants will be randomly assigned to one of two groups. The experimental group will receive postural mobilization involving passive leg raising, where the legs are elevated to about a 45° angle to help manage hemodynamics. The control group will receive hemodynamic management exclusively with noradrenaline, without postural mobilization. These procedures take place during the open-heart off-pump CABG surgery. During the study, researchers will monitor the use of noradrenaline throughout the surgery and assess hemodynamic management during a 30-day follow-up period. They will evaluate patient outcomes including revascularization success and any postoperative complications. This single-center study involves adult patients who undergo elective or emergency isolated coronary bypass surgery and includes assessments of heart function and safety monitoring throughout the perioperative period.

Alzheimer's disease and related disorders (ADRD) are highly disabling conditions characterized by cognitive decline, loss of functional independence, and behavioral changes. Since there is no current cure, this research focuses on identifying factors that predict how the disease progresses, particularly by tracking changes in patients' ability to function independently over time. The study involves about 1000 patients with memory impairment and will follow them for three years to gather important information. Participants will be patients visiting a Memory Clinic for the first time, living either at home or in housing, and at any stage of memory impairment. The study collects data by regularly assessing patients' functional autonomy every 6 to 12 months using tools such as the Lawton Instrumental Activities of Daily Living score (IADL) and the Disability Assessment of Dementia score (DAD-6). These assessments are conducted by phone to monitor changes in their daily living abilities. Throughout the three-year follow-up, researchers will track how patients' functional autonomy changes and analyze factors that may predict this progression. Data collection includes phone assessments every 6 to 12 months, with a focus on the level of independence in daily activities. This ongoing monitoring aims to improve understanding of ADRD progression and support better management of patients' needs over time.

Alzheimer's disease and related disorders (ADRD) are among the most disabling illnesses due to cognitive decline, loss of functional independence, and behavioral changes. Without a current cure, identifying risk factors that predict disease progression by tracking key symptoms is a crucial public health priority. Researchers aim to develop a regional database of patient medical records in collaboration with healthcare and computer science teams to support this goal. The study will observe about 5400 patients with memory disorders across centers in the Auvergne Rhone-Alpes region in France. There is no intervention or treatment being tested; patients will undergo routine medical examinations in memory centers that include detailed and standardized assessments such as IADL, DAD6, New AGGIR, NPI, and mini-Zarit to evaluate autonomy, behavior, and caregiver burden. The inclusion period is planned for 3 years, with each patient followed up for up to 10 years, making the total study duration 13 years. Participants will have their functional autonomy level measured every 6 to 12 months to monitor changes over time. The study collects extensive data on patient function, behavior, and caregiver impact through these evaluations. This long-term, real-life observational approach is designed to identify factors linked to autonomy loss in patients with ADRD, supporting better understanding and management of the disease.